Innovent Announces First Patient Dosed in Phase I Clinical Trial of Anti-CD47 Monoclonal Antibody in the U.S.
(WorldNews Health)

SUZHOU, China, March 18, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the first patient has been successfully dosed in a Phase I clinical trial of anti-cluster of differentiation 47 (anti-CD47) monoclonal antibody drug candidate (IBI188) in the United States (U.S.). The CIBI188A102 study (CIBI188A102) is a Phase I clinical study conducted in the U.S. to evaluate IBI188 in patients with advanced malignant tumors. The primary objectives are to evaluate the safety and tolerability, and to define the Phase II clinical trial recommended doses...